Adams Dental Clinic | |
149 S. Main St. Adams WI 53910-0159 | |
(608) 339-6613 | |
(608) 339-3936 |
Full Name | Adams Dental Clinic |
---|---|
Speciality | Dentist |
Location | 149 S. Main St., Adams, Wisconsin |
Authorized Official Name and Position | Joseph Ray Parlante (DENTIST/OWNER) |
Authorized Official Contact | 6083396613 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Adams Dental Clinic Po Box 159 149 S. Main St. Adams WI 53910-0159 Ph: (608) 339-6613 | Adams Dental Clinic 149 S. Main St. Adams WI 53910-0159 Ph: (608) 339-6613 |
NPI Number | 1053671107 |
---|---|
Provider Enumeration Date | 05/23/2012 |
Last Update Date | 05/23/2012 |
Identifier | Type | State | Issuer |
---|---|---|---|
1053671107 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
122300000X | Dentist | 3813-015 (Wisconsin) | Primary |
News Archive
Many of the nation's physicians are now involved in the effort to eliminate racial and ethnic health care disparities, according to a recent survey released by the Commission to End Health Care Disparities.
In a Los Angeles Times opinion piece, Evan Wood, associate professor of medicine at the University of British Columbia, writes about the Vienna Declaration, a document he helped to draft, that calls for international leaders to revise drug policies to incorporate greater scientific evidence and promote HIV prevention, treatment and care for drug users.
CVRx, Inc., a privately held medical device company, announced today that CE Marking has been granted to expand labeling of the Barostim neo System as MR Conditional, or safe for use in Magnetic Resonance Imaging (MRI) systems under specified conditions.
Whether the brain responds to an external stimulus or not depends significantly on the balance between areas of excitation and inhibition in the prefrontal cortex (PFC).
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Jiangsu Hengrui Medicine Co., Ltd., a leading Chinese pharmaceutical company, today announced that Shanghai ChemPartner, a wholly owned subsidiary of ShangPharma, and Hengrui have entered into a strategic partnership for the development of novel therapeutic monoclonal antibodies.
› Verified 6 days ago